Application of fructus schisandrae total polysaccharides in preparatoin of medicine or nutraceuticals used for treating coughing

Abstract

The present invention relates to a new application of Fructus schisandrae total polysaccharides in preparation of medicine or nutraceuticals for treating coughing, and more specifically to a new application of Fructus schisandrae total polysaccharides in preparation of medicine or nutraceuticals for preventing and relieving coughing and eliminating airway inflammation. Experiments demonstrate that the Fructus schisandrae total polysaccharides can remarkably reduce the coughing times of a guinea pig with increased cough sensitivity induced by cigarette smoke and an acute cough guinea pig induced by citric acid smoke, prolong the latent period of cough, and significantly reduce the airway inflammation of the guinea pig with increased cough susceptibility induced by cigarette smoke, so that the Fructus schisandrae total polysaccharides can be used for preparing drugs for preventing cough, relieving cough and eliminating airway inflammation.

Claims

1. An application of Fructus schisandrae total polysaccharides in preparation of medicine or nutraceuticals used for treating coughing, characterized in that the medicine or nutraceuticals are used for treating acute cough, sub-acute cough or chronic cough; and the Fructus schisandrae total polysaccharides are prepared through the following steps: pulverizing Fructus schisandrae, degreasing the pulverized Fructus schisandrae with petroleum ether, decocting the degreased Fructus schisandrae for three times by using 8 times water, concentrating obtained decocted liquid, precipitating the concentrated solution by using 80% ethanol, filtering, performing deproteinization through a precipitation enzymatic method, decoloring by using active carbon, repeatedly washing by using 80% ethanol, and then drying to obtain the Fructus schisandrae total polysaccharides, and the content of polysaccharides in the Fructus schisandrae total polysaccharides is 89% through test on the basis of D-glucose.

2. The application according to claim 1, characterized in that the medicine or nutraceuticals are used for preventing cough, relieving cough or eliminating airway inflammation.

3. The application according to claim 1, characterized in that the Fructus schisandrae total polysaccharides are extracted from Fructus schisandrae, and the Fructus schisandrae is at least one of Schisandra chinensis (Turcz.) Baill. and Schisandra sphenanthera Rehd. et Wils.

4. The application according to claim 1, characterized in that the Fructus schisandrae total polysaccharides are made into pharmaceutically acceptable dosage forms.

5. The application according to claim 4, characterized in that dosage forms are tablets, hard capsules, soft capsules, powder, tinctures, oral solutions, syrups, granules, pills or injections.

6. The application according to claim 2, characterized in that the Fructus schisandrae total polysaccharides are extracted from Fructus schisandrae, and the Fructus schisandrae is at least one of Schisandra chinensis (Turcz.) Baill. and Schisandra sphenanthera Rehd. et Wils.

Description

DESCRIPTION OF THE DRAWINGS

(1) FIG. 1 is a representative graph (HE*200) of a guinea pig lung tissue and airway pathological section in embodiment I.

(2) FIG. 2 is a graph showing the impact of the Fructus schisandrae total polysaccharides on the coughing times of citric acid smoke stimulation-caused guinea pigs at different time points.

DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS

(3) The present invention is further described below in details in conjunction with embodiments and drawings, but the present invention is not limited to the following embodiments.

(4) Experimental animals used in the specific embodiments are ordinary male pure white Hartly guinea pigs each with a weight of 30050 g which are supplied by the Laboratory Animal Center of Guangdong Province (SCXK (Guang) 2008-0002). The guinea pigs are raised in a relatively clean and quiet environment with constant temperature (233 C.) and constant humidity (5515%); the diurnal cycle is 12:12 h/day; and the guinea pigs are raised in different cages, and every five guinea pigs are raised in one cage and can obtain food and water freely.

(5) Drugs, reagents and instruments used in the specific embodiments:

(6) (1) Fructus schisandrae total polysaccharides, the preparation steps are as follows:

(7) Pulverizing the Fructus schisandrae, degreasing the pulverized Fructus schisandrae with petroleum ether and then decocted in water of 8-times quantity three times, concentrating the decocted liquid, precipiptating by using 80% ethanol, filtering, performing deproteinization through an enzyme precipitation method, decoloring by using active carbon, repeatedly washing by using 80% ethanol, and then drying to obtain the Fructus schisandrae total polysaccharides; and the content of the polysaccharides is 89% through test on the basis of D-glucose;

(8) (2) water extract from Fructus schisandrae, the preparation steps are as follows:

(9) pulverizing Fructus schisandrae.fwdarw.decocting for 2 h with water of eight-times quantity for three times.fwdarw.concentrating decocted liquid, drying.fwdarw.water extract from Fructus schisandrae;

(10) (3) 0.9% sodium chloride injection: Dongguan Puji pharmaceutical co., Ltd. Pentobarbital sodium: American Merck Company. Codeine China National Pharmaceutical Industry Co., Ltd. Red Rose filter-tipped cigarettes: China Tobacco Guangzhou Industrial Co., Ltd. Other conventional reagents: Guangzhou Chemical Reagent Factory.

(11) (4) Experimental instruments: PM single-cavity nonrestrictive small animal plethysmography (1.0 L): American Buxco Company; an integrated system of digital photography: Japan Nikon Company; a 0.6 m*0.6 m*1 m cigarette smoke poisoning box: made by the laboratory; A1003 electronic scales: German Satorius Company; a MDF-U53V 80 C. low-temperature refrigerator: Japan Sanyo Company; a 3-18 k SIGMA high-speed freezing centrifugal machine: America Beckman Company; 22 G venous indwelling needles: Suzhou Medical Instrument. Co., Ltd; an Anke TGL-168-type ordinary high-speed centrifugal machine: Shanghai Anting Scientific Instrument Factory; a 400-type table-type low-temperature centrifugal machine: German Heraeus Company; XW80A-type vortex oscillator: Shanghai Precision Instrument Co., Ltd; a DK8A constant-temperature water-bath kettle: Shanghai Jinghong Test Instrument Co., Ltd.

(12) In the detailed description, all data are expressed by using mean valuestandard deviation; one-way analysis of variance is carried out for the comparison of different groups by using spss13.0; the homogeneity of variance is tested by using a least significant difference (LSD) method; rank sum test is adopted for non-homogeneity of variance or abnormal data; and P<0.05 indicates that the difference has statistical significance.

Embodiment I: Pharmacologic Action of Fructus Schisandrae Total Polysaccharides to Guinea Pigs with Increased Cough Sensitivity Induced by Cigarette Smoke

(13) 1.1 Smoking method: prior to the experiment, after being adaptively raised quietly for one week, the guinea pigs are placed in a self-made cigarette poisoning box; ten cigarettes are fired every time and placed in a smoking trough (flume-cured tobacco type, content of tar is 12 mg, content of nicotine in smoke is 1.1 mg, and content of carbon oxide in the smoke is 15 mg); and the cigarette smoke is led into the poisoning box by three-way valve, and the timing is started after the cigarette is burnt out. The guinea pigs are smoked for 20 minutes every time and twice a day; and the smoking interval time between two adjacent smoking is greater than 6 h; and the guinea pigs are consecutively smoked for 14 days.

(14) 1.2 Experiment:

(15) The guinea pigs are randomly divided into a normal group, a model group, a solvent reference group (0.5% PEG400), a codeine group, a water extract high dose group (dose: 500 mg/kg guinea pig/day: drug concentration: 50 m/mL), a total polysaccharides high dose group (dose: 500 mg/kg guinea pig/day; drug concentration: 50 mg/mL), a total polysaccharides middle dose group (dose: 250 mg/kg guinea pig/day; drug concentration: 25 mg/mL) and a total polysaccharides low dose group (dose: 125 mg/kg guinea pig/day, drug concentration: 12.5 mg/mL).

(16) Except for the normal group, animals in other groups are respectively stimulated by adopting the smoking method described in the above 1.1. Except for the normal group and the codeine group, the guinea pigs in the other groups are orally given with the corresponding drugs or solvent two hours before the second smoking for 14 consecutive days from the first day of smoking. The guinea pigs of the codeine group is orally administrated (30 mg/kg guinea pig; the codeine concentration: 3 mg/mL) one hour before the citric acid cough sensitivity check. The guinea pigs of the normal group are normally raised without any treatment. The guinea pigs are placed in a plethysmogrophy box at the 15th day; two minutes later, 0.4 mol/L citric acid aqueous solution is atomized to perform the cough stimulation, and the atomizing is ended in 10 minutes; the guinea pigs are continuously observed for 10 minutes; and the coughing times and coughing latent period of the guinea pigs in 20 minutes after the atomizing is started are recorded.

(17) Intraperitoneal injection with 3% pentobarbital sodium solution (1 mL/kg) is performed to anesthetize the animal in 24 hours after the cough stimulation test, and 10 mL of blood is taken from the heart of the animal. The bronchoalveolar lavage fluid (BALF) is obtained by taking 6 mL of 0.1 mol/L pre-cooled PBS buffer solution, performing the bronchoalveolar lavage for three times, and uniformly lavaging the left lung repeatedly for three times. The resultant BALF is shaken and suspended; 0.5 mL of the BALF is drawn to be sufficiently splitted by using red blood cell lysate and then centrifuged for 10 minutes at 3000 rpm; 10 L of supernatant is dropped into a blood cell counting plate; a total number of BALF inflammatory cells is calculated under the optical microscope (total number of cells/mL=(total number of four lattices of cells/4*10.sup.4/mL); the remaining BALF is centrifuged for 10 minutes at 3000 rpm and precipitated by using 1 mL of PBS suspension; 100 L is used for making a cell smearer, the cell smearer is naturally dried, immersed in 10% neutral formaldehyde over a night and fixed; then the cell smearer is taken out and successively washed for 10 minutes by using flowing water, stained for 15 seconds by using hematoxylin, washed for one minute by using flowing water, decolored for 2 seconds by using 1% hydrochloric acid alcohol, washed for 10 minutes by using flowing water, stained for 5 seconds by using eosin, washed for 10 minutes by using flowing water and dried to obtain a cell smearer sealed by neutral gum; 20 neutral gum sealed smearers are consecutively and randomly extracted to be continuously counted at 400 times of magnifications under the optical microscope; 400 cells are consecutively counted on each smearer to calculate a ratio of neutrophils, eosinophils, macrophages and lymphocytes.

(18) After the BALF is extracted from the guinea pigs, 50 mL of PBS is injected into the heart of the guinea pig to perform the lavage; 2.5 mL of 4% paraformaldehyde is injected from trachea; then a section of right lower lung tissue and a section of trachea are cut and fixed for more than 24 h by using 10% neutral formaldehyde. The fixed lung tissue is taken out and successively dehydrated by gradient ethanol, treated by biological clarifier, waxed, embedded, sectioned, dewaxed, hydrated by gradient alcohol, temporarily rinsed by double distilled water, finally stained by hematoxylin eosin (HE) and sealed by neutral gum to carry out the pathology observation.

(19) Experimental result: compared with the normal group, the guinea pigs in each experimental group are not obviously different in airway resistance, which indicates that the experiment modeling method does not lead to the increase of the airway resistance of the guinea pigs and is different from that of a chronic obstructive pulmonary disease animal model.

(20) The citric acid-stimulated coughing times of the guinea pigs in each experimental group is shown in table 1. The results show that, compared with the model group, the total polysaccharides (high and middle dose groups) show a significant reduction in the activity of coughing times, while the total polysaccharides at a low dose have no statistical significance on suppressing the coughing times but have a tendency of reducing the coughing times, showing a certain dose dependency: and compared with the model group, the coughing times of the guinea pigs in the water extract high-dose group have no significant difference.

(21) TABLE-US-00001 TABLE 1 Impact on coughing times of the guinea pigs with increased cough sensitivity induced by cigarette smoke in each experimental group (x s)(n = 7-10) Group Dose Coughing times Normal group 32.43 14.39**## Model group 64.29 12.54 Solvent reference 10 mL/kg 59.86 12.46 group Codeine group 30 mg/kg 37.29 11.64**## Water extract high 500 mg/kg 58.43 16.46 dose group Total 500 mg/kg 26.00 17.31**## polysaccharides high dose group Total 250 mg/kg 41.71 15.10*# polysaccharides middle dose group Total 125 mg/kg 49.71 8.92* polysaccharides low dose group Note: compared with the model group, *P < 0.05, and **P < 0.01; and compared with the water extract high dose group, #P < 0.05 and ##P < 0.01.

(22) The coughing latent period of each experimental group is shown in table 2. The result shows that, compared with the model group, the total polysaccharides of a high dose, a middle dose and a low dose can remarkably prolong the coughing latent period, but the action of the water extract of a high dose on the coughing latent period is not obvious

(23) TABLE-US-00002 TABLE 2 Impact on coughing latent period of the the guinea pigs with increased cough sensitivity induced by cigarette smoke in each experimental group (x s)(n = 7-10) Coughing latent Group Dose period (s) Normal group 182.28 39.86**# Model group 80.28 25.32 Solvent reference 10 mL/kg 85.28 21.28 group Codeine group 30 mg/kg 186.14 45.27**# Water extract high 500 mg/kg 106.71 37.82 dose group Total 500 mg/kg 220.71 52.16**## polysaccharides high dose group Total 250 mg/kg 189.14 43.07**# polysaccharides middle dose group Total 125 mg/kg 122.57 30.62* polysaccharides low dose group Note: compared with the model group, *P < 0.05, and **P < 0.01; and compared with the water extract high dose group, #P < 0.05.

(24) Total number of inflammatory cells in BALE and the classified comparison experimental results are shown in table 3. The results show that compared with the model group, the total polysaccharides of a high dose, a middle dose and a low dose can remarkably reduce the total number of the inflammatory cells in BALE; and the total polysaccharides of the high and middle doses can remarkably reduce the ratio of the neutrophil in the BALF. The total number of BALF cells and the classified counts of cells of the guinea pigs in the water extract high dose group are not greatly different from that of the model group.

(25) TABLE-US-00003 TABLE 3 Impact on the total number and classification of BALF inflammatory cells of the the guinea pigs with increased cough sensitivity induced by cigarette smoke in each experimental group (x s)(n = 7-10) total number of Group cells * 10.sup.6/mL Mac % Neu % Lym % Eos % Normal group 0.98 0.22**## 75.43 12.14 6.93 5.50 3.36**## 2.64**## 2.73 3.93 Model group 1.97 0.36 44.50 47.29 2.79 4.71 4.76 5.69 1.75 2.33 Solvent 1.92 0.43 42.79 46.00 5.00 5.43 reference group 5.45 5.09 1.83 2.47 Codeine group 2.13 0.38 43.86 48.10 3.64 4.25 4.26 3.28 0.84 1.36 Water extract 1.76 0.36 46.79 43.86 4.57 5.64 high dose group 6.96 4.55 3.65 4.39 Total 1.26 0.28**## 56.96 33.14 3.46 2.57 polysaccharides 6.58**## 6.98**## 1.56 2.50 high dose group Total 1.38 0.32**# 51.86 37.64 4.25 2.61 polysaccharides 5.64** 5.75**# 3.23 2.30 middle dose group Total 1.54 0.40* 47.86 42.00 2.89 3.75 polysaccharides 6.65 5.17 1.85 2.75 low dose group Note: compared with the model group, *P < 0.05, and **P < 0.01; and compared with the water extract high dose group, #P < 0.05 and ##P < 0.01.

(26) The observation result of the pathological section shows that, compared with the model group, the pathology of the lung tissues and trachea of the guinea pigs given with different doses of the total polysaccharides are obviously improved: the inflammatory cell invasion around the bronchiole of the guinea pigs is obviously reduced, the endobronchial inflammatory exudate is alleviated, the alveolar septum broadening degree is reduced, which indicates that the Fructus schisandrae total polysaccharides have an obvious action on alleviating the lung and airway inflammation. But the pathology of the lung tissues and trachea of the guinea pigs given with high dose of water extract is not obviously improved. The guinea pig tissue and trachea pathological section representative graph is shown in FIG. 1.

(27) The experimental result of embodiment I shows that the Fructus schisandrae total polysaccharides have an obvious action on reducing the coughing times, prolonging the latent period of cough and alleviating the lung and airway inflammation to the guinea pigs with increased cough sensitivity induced by cigarette smoke.

Embodiment II

(28) After the guinea pigs are quietly raised for one week, the cough sensitivity screening is carried out: the guinea pigs is stimulated for one minute by atomizing 0.8 mol/L citric acid and continuously observed for five minutes; the coughing times of the guinea pigs in 6 minutes after the atomizing is started is recorded; and the guinea pigs with the coughing times greater than 10 times and less than 50 times are the qualified guinea pigs.

(29) The qualified guinea pigs are selected to be randomly divided into a normal group, a solvent reference group (0.5% PEG400), a codeine group, a water extract high dose group (dose: 500 mg/kg guinea pig day: drug concentration: 50 mg/mL), a total polysaccharide high dose group (dose: 500 mg/kg guinea pig/day; drug concentration: 50 mg/mL), a total polysaccharide middle dose group (dose: 250 mg/kg guinea pig/day: drug concentration: 25 mg/mL) and a polysaccharide low dose group (dose: 125 mg/kg guinea pig/day: drug concentration: 12.5 mg/mL).

(30) Except for the normal group and the codeine group, the guinea pigs in the rest groups are orally given with drugs or solvent consecutively for five days and once a day; and the citric acid cough stimulation is carried out in one hour after the guinea pigs are given with the drug or solvent at the fifth day: the guinea pigs are stimulated for one minute by atomizing 0.8 mol/L citric acid and are continuously observed for 5 minutes after the atomizing is stopped, and the coughing times of the guinea pigs in 6 minutes after the atomizing is started is recorded. The guinea pigs of the codeine group are orally given with the drug in one hour before the citric acid cough stimulation at the fifth day. The guinea pigs of the normal group are raised normally and are directly stimulated by the citric acid at the fifth day.

(31) The coughing times of the guinea pigs in each experimental group are shown in table 4. The result shows that, compared with the normal group, the coughing times of the guinea pigs intervened with the high dose, middle dose and low dose of total polysaccharides is remarkably reduced, while the coughing times of the guinea pigs intervened with the high dose of water extract has no significant difference.

(32) TABLE-US-00004 TABLE 4 Impact on the coughing times of the acute cough guinea pigs induced by citric acid smoke (x s) (n = 8) Group Dose Coughing times Normal group 24.00 4.90 Solvent reference group 10 mL/kg 21.67 4.46 Codeine group 30 mg/kg 3.83 1.94**## Water extract high 500 mg/kg 19.17 4.36 dose group Total 500 mg/kg 3.50 1.87**## polysaccharides high dose group Total 250 mg/kg 7.5 3.27**## polysaccharides middle dose group Total 125 mg/kg 12.17 3.19**## polysaccharides low dose group Note: compared with the normal group, **P < 0.01; and compared with the water extract high dose group, ##P < 0.01.

(33) The coughing latent period of the guinea pigs in each experimental group is shown in table 5. The results show that, compared with the normal group, the coughing latent period of the guinea pigs intervened with the high dose, middle dose and low dose of total polysaccharides is remarkably prolonged, while the coughing latent period of the guinea pigs intervened with high dose of water extract has no significant difference.

(34) TABLE-US-00005 TABLE 5 Impact on the coughing latent period of the acute cough guinea pigs induced by citric acid smoke (x s) (n = 8) Coughing latent Group Dose period (s) Normal group 39.67 13.53 Solvent reference group 10 mL/kg 31.17 13.23 Codeine group 30 mg/kg 115.3 20.18**## Water extract high 500 mg/kg 42.69 10.76 dose group Total 500 mg/kg 132.3 40.51**## polysaccharides high dose group Total 250 mg/kg 104.5 22.51**## polysaccharides middle dose group Total 125 mg/kg 68.33 17.14**# polysaccharides low dose group Note: compared with the normal group, *P < 0.05, and **P < 0.01; and compared with the water extract high dose group, #P < 0.05 and ##P < 0.01.

(35) The results of embodiment II show that the Fructus schisandrae total polysaccharides can remarkably reduce the coughing times and can prolong the coughing latent period of the acute cough guinea pigs induced by citric acid smoke, and show an application potential in the aspect of treating the acute cough.

Embodiment III

(36) After the guinea pigs are quietly raised for one week, the cough sensitivity is screened: the guinea pigs are stimulated for one minute by atomizing 0.8 mol/L citric acid and continuously observed for five minutes after the atomizing is stopped; the coughing times of the guinea pigs in 6 minutes after the atomization is started is recorded; and the guinea pigs with the coughing times greater than 10 times and less than 50 times are the qualified guinea pigs.

(37) The qualified guinea pigs are selected to be normally raised for three days and randomly divided into four groups with 30 guinea pigs in each group. The guinea pigs in the first group are divided into three subgroups with 10 guinea pigs in each subgroup, and all guinea pigs are directly under the citric acid cough stimulation: the guinea pigs are stimulated for one minute by atomizing 0.8 mol/L citric acid and are continuously observed for 5 minutes after the atomization is stopped, and the coughing times of the guinea pigs in 6 minutes after the atomization is started is recorded. The guinea pigs in the second group are randomly divided into three subgroups, i.e. a normal group, a codeine group (30 mg/kg, oral administration), a Fructus schisandrae total polysaccharides group (500 mg/kg, drug concentration: 50 mg/mL, orally administration), and each subgroup contains 10 guinea pigs; the normal group is directly under the citric acid cough stimulation; the codeine group and the Fructus schisandrae total polysaccharides group are under the cough stimulation in one hour after being administrated, and the stimulation condition is the same with that of the first group; and the grouping and stimulation conditions of the third group and the fourth group are the same with that of the second group, and the codeine group and the Fructus schisandrae total polysaccharides group are respectively administrated in three hours and five hours before the stimulation. The results are as shown in FIG. 2 and show that the acute coughing times of the citric acid smoke stimulation-caused guinea pigs can be remarkably reduced in one hour after the guinea pigs are given with the Fructus schisandrae total polysaccharides (500 mg/kg) for one time: the drug effect is still significant in 5 hours after the Fructus schisandrae total polysaccharides are administrated; and the coughing times of the guinea pigs in 5 hours after the guinea pigs are given with the codeine have no significant difference with that of the normal group.

(38) As can be seen from embodiment I to embodiment III, the Fructus schisandrae total polysaccharides can remarkably prolong the latent period of the cough and reduce the coughing times of the guinea pigs with increased cough sensitivity induced by cigarette smoke and the acute cough guinea pig induced by citric acid smoke, prolong the latent period of cough, and can remarkably reduce the total number of inflammatory cells and the ratio of neutrophil in the bronchoalveolar lavage solution of the guinea pigs with increased cough sensitivity induced by cigarette smoke. It is noted that the inflammatory cell invasion around the guinea pig bronchiole after the intervention of the Fructus schisandrae total polysaccharides can be obviously reduced from the observation of a pathological section, the endobronchial inflammatory exudate is reduced, the broadening degree of the alveolar septum is reduced, and it shows that the Fructus schisandrae total polysaccharides has a remarkable suppression effect on the airway inflammation of the guinea pigs. Moreover, the effect of the Fructus schisandrae total polysaccharides is obviously better than that of water extract from Fructus schisandrae, and the Fructus schisandrae total polysaccharides have a given dose-effect relationship and have the application prospect in the aspect of preventing cough, relieving cough and eliminating airway inflammation.

Embodiment IV (an Example of Preparing Syrup Containing the Fructus Schisandrae Total Polysaccharides)

(39) 2 kg of Fructus schisandrae total polysaccharides are dissolved in an appropriate amount of water to prepare a Fructus schisandrae total polysaccharides solution for standby use; 2 kg of sucrose is boiled in water and uniformly mixed with the prepared Fructus schisandrae total polysaccharides solution and 4 g of sodium benzoate and stands, the supernatant is uniformly mixed with water to reach 2000 mL to obtain Fructus schisandrae total polysaccharides syrup. The syrup is sub-packaged with 100 mL in each bottle.

(40) Method for taking the syrup: the syrup is taken one to three times a day with 10 mL for each time, and the amount of the syrup for the patient in a serious condition can be increased appropriately.

(41) In the present embodiment, the Fructus schisandrae total polysaccharides are prepared by adopting the extraction process described hereinabove and prepared in the following specific steps: the Fructus schisandrae is pulverized, the pulverized Fructus schisandrae is degreased with petroleum ether and then decocted in 8 times water for three times, the decocted liquid is concentrated, the concentrated liquid is precipitated by using 80% ethanol, filtered, deproteinized through an enzyme precipitation method, decolored by using active carbon, repeatedly washed by using 80% ethanol, and then dried to obtain the Fructus schisandrae total polysaccharides; and the content of the polysaccharides is 89% through test on the basis of D-glucose.

Application Example

(42) The Fructus schisandrae total polysaccharides syrup prepared in the embodiment IV has already been clinically tested, wherein there are 12 cases of chronic cough patients and 11 cases of acute cough patients; the patients drink the syrup prepared in the embodiment IV one to three times a day with 10 mL at each time consecutively for one to two weeks, the total effective rate is 100%, and the specific feedback results are shown in the table below.

(43) TABLE-US-00006 Case Excellent effect Effective Noneffective acute cough 8 3 0 chronic cough 9 3 0

(44) Three typical cases are described in detail below:

(45) Case 1: Mr. Wen, Male, 50 years old, coughing for about three months, diagnosed with cough hypersensibility syndrome, and continuously taking the Fructus schisandrae total polysaccharides syrup for one week; the cough sensitivity is remarkably alleviated, and the coughing times are significantly reduced.

(46) Case 2: Mr. Xi, 25 years old, coughing for about one month, diagnosed with post-cold cough, and taking two bottles of the Fructus schisandrae total polysaccharides syrup; and the syrup takes effect at the first day, and the cough is basically alleviated.

(47) Case 3: Mrs. Kong, 46 years old, coughing for about one month, having sputum obstruction, difficult to cough up the sputum, diagnosed with post-infective cough, and taking two bottles of the Fructus schisandrae total polysaccharides syrup; and the syrup takes effect at the second day, the patient gets better by 70%, and after taking one more bottle of syrup, the cough of the patient is basically completely alleviated.

(48) Case 4: Mr. Yu, 36 years old, coughing for about one year, having dry cough, diagnosed with eosinophils bronchitis, having gastroesophageal reflux cough and taking two bottles of Fructus schisandrae total polysaccharides syrup; the drug takes effect at the third day; the patient gets better by 40%; and after the patient takes two bottles of Fructus schisandrae total polysaccharides syrup, the cough symptom is basically eliminated.

(49) As is known from the above embodiments, the cough can be effectively relieved by orally taking the Fructus schisandrae total polysaccharides syrup, and the airway inflammation can be alleviated. Moreover, the Fructus schisandrae total polysaccharides are extracted from the traditional Chinese medicine Fructus schisandrae; and the Fructus schisandrae is the traditional Chinese medicine available for the health food published by the ministry of health and has no toxicity and side effect to the human body. The Fructus schisandrae total polysaccharides are made into syrup and also can be made into other pharmaceutically acceptable dosage forms by those skilled in, the art according to the need such as tablets, hard capsules, soft capsules, powder, tinctures, pills, granules, injections or other orally liquid forms.

(50) The above only describes preferred embodiments of the present invention, and is not intended to limit the present invention in any form. Therefore, any simple alteration, equivalent changes and modifications made to the above embodiments based on the technical essence of the present invention without departing from the technical solution of the present invention shall still belong to the scope of the technical solution of the present invention.